Autolus Therapeutics plc (AUTL) stock
Close on Nov 11, 2026Market cap $328.71MP/E –Yield –
Autolus Therapeutics plc grew revenue 168.8% to $137.43M over the twelve months to Sep 30, 2026. Free cash flow was -$180.20M. At the latest close the market valued the company at $328.71M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $328.71M
- P/E ratio
- –
- Price to sales
- 2.39
- Price to book
- 12.00
- Dividend yield
- –
- Free cash flow yield
- -54.82%
Fundamentals
- Revenue
- $137.43M
- Net income
- -$256.13M
- EPS, diluted
- -$0.97
- Free cash flow
- -$180.20M
- Book value per share
- $0.10
- Diluted shares
- 266M
Trading
- Next earnings
- Mar 26, 2027 (estimated, before the open)
- Previous close
- $1.32
- Open
- $1.32
- Day's range
- $1.20 – $1.33
- Volume
- 3,847,312
- Average volume (20 days)
- 2,604,614
- Beta (5 years)
- 1.85
- 52-week range
- $1.12 – $2.58
- RSI (14 days)
- 27.7
- Volatility (1 year)
- 75.1%
- Relative volume
- 1.79×
- WACC
- 14.1%
Market cap history
Month-end market cap since 2018, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | AUTL | S&P 500 | Difference | AUTL per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -31.8% | -2.4% | −29.4 pts | ||
| 3 months | -47.0% | -1.2% | −45.8 pts | ||
| Year to date | -37.9% | +12.3% | −50.2 pts | ||
| 1 year | -17.7% | +12.4% | −30.1 pts | ||
| 3 years | -64.0% | +78.8% | −142.8 pts | -28.9% | +21.4% |
| 5 years | -81.7% | +75.2% | −156.9 pts | -28.8% | +11.9% |
Ten years at a glance
Fiscal years 2015 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Autolus Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Update
- News
About Autolus Therapeutics
Biological Products, (No Diagnostic Substances)
The company is an early commercial-stage biopharmaceutical business that develops, manufactures, and supplies programmed T-cell immunotherapies for patients with cancer and autoimmune conditions. Its lead commercial therapy is AUCATZYL, an autologous CAR T-cell treatment directed against the CD19 antigen for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. The firm also advances a pipeline of investigational candidates for additional hematological malignancies, solid tumors, lupus nephritis, and progressive multiple sclerosis. Its recipients and end users are patients treated through authorized specialized hospital treatment centers.
Company profile, executives and historyAutolus Therapeutics stock: common questions
What is Autolus Therapeutics's stock price?
AUTL closed at $1.24 on Nov 11, 2026, down 6.44% on the day. Over the past 52 weeks it traded between $1.12 and $2.58.
What is Autolus Therapeutics's market cap?
Autolus Therapeutics was worth $328.71M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is AUTL's P/E ratio?
Autolus Therapeutics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.97), so it has no meaningful P/E ratio.
How much revenue does Autolus Therapeutics make?
Autolus Therapeutics reported revenue of $137.43M for the twelve months to Sep 30, 2026, up 168.8% from a year earlier.
Does Autolus Therapeutics pay a dividend?
No. Autolus Therapeutics has not paid a cash dividend over the last twelve months.
When does Autolus Therapeutics report earnings next?
Autolus Therapeutics is expected to report Q4 FY2026 results on Mar 26, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has AUTL stock performed over the past year?
Including dividends, AUTL returned -17.7% over the past year, against +12.4% for the S&P 500.
Who are Autolus Therapeutics's competitors?
Companies most similar to Autolus Therapeutics by business, industry and size include ADAPY, IPSC, MESO, CHRS, IOVA.
See a number that looks wrong?